Fauci also said in the CBS interview that the United States was unlikely to have 100 million doses of a vaccine deemed by regulators as "safe and effective" available by the end of the year, contrary to a claim Trump made in September.
The Indian leadership is hoping for a COVID-19 Vaccine by early next year.
The news comes two months after Russian Federation approved its first vaccine, Sputnik V, for use by the public, also before mass testing had taken place.
The world's largest country is expected to register its second potential coronavirus vaccine this week following the completion of early-stage human trials. However, results have not been published yet and a large-scale trial, known as Phase III, has not yet begun. "Such vaccines mimic certain parts of the pathogen they are created to protect from, making the human body produce antigens capable of fighting the real virus", according to the Sputnik news agency.
Sputnik V was developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.
"In our opinion, the situation is manageable and does not require the introduction of restrictions on the economy", Deputy Prime Minister Tatiana Golikova said at a government meeting headed by Putin.
How The Supreme Court Confirmation Hearings For Amy Coney Barrett Will Work
After the committee completes the hearings, which is expected to happen on Thursday, Graham can move for a committee vote. The Supreme Court is scheduled to hear arguments on November 10 regarding whether the whole law should be tossed out.
The Russian President further said that production needed to be increased on the first and second vaccine.
After creating a hubbub with the first vaccine Sputnik V against the Coronavirus, Russia came up with a second vaccine named EpiVacCorona, which got regulatory approval from the Russian authorities.
Golikova also informed media persons that the Vector centre is starting post-registration clinical trials in various regions of Russian Federation and would include 40,000 volunteers.
Post-registration clinical trials involving more than 40,000 people in Russian Federation started on August, 24.